$MRSH

Yates Lloyd M sold $2.1M of MRSH

Yates Lloyd M sold 12,000 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $175.65 ($2.11M total) on 2026-07-23.

Original reporting
SEC EDGAR · Yates Lloyd M
Published Jul 24, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MRSH
Neutral
medium confidence
Mentioned
$MRSH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may note the sale for sentiment monitoring, but there is no accompanying company-specific catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context or repeated sales, signal quality is low.

Relevance 6/10Novelty 3/10Timing: Filed 2026-07-24, discloses sale executed 2026-07-23.

Background

The article is a SEC Form 4 insider transaction disclosure for Marsh & McLennan (MRSH).

Company-level read

Ticker impact

$MRSHNeutralMedium confidence
Context

Marsh & McLennan director Yates Lloyd M sold 12,000 shares on 2026-07-23 at $175.65, totaling $2.11M, per Form 4.

Expected impact

Likely limited near-term impact; treat as routine insider liquidity unless follow-on filings suggest broader selling.

Evidence & confidence

The article provides a single Form 4 sale with no 10b5-1 plan and no accompanying company-specific news, so the incremental trading signal is modest.

Market effects

No sector read-across is provided; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as less “mechanical” selling, but the filing alone does not establish intent or future sales.

Key entities

  • Marsh & McLennan Companies, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Yates Lloyd M

    Director who sold 12,000 shares on 2026-07-23.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRSHMedAI 8/10

Why Marsh (MRSH) Stock Is Trading Up Today

Marsh (MRSH) shares rose 4.7% after reporting Q3 2026 results with 8% revenue growth and 10% increase in adjusted EPS. GAAP earnings were $1.69, adjusted earnings $2.03. The company repurchased $500M in stock and raised its savings target to $600M. Shares closed at $186.43, up 4.5%.

$MRSHHighAI 8/10

Marsh McLennan earnings analysis: questions answered and next catalysts

Marsh McLennan (MRSH) reported Q3 FY2026 earnings on Oct 15, 2026, beating estimates with EPS of $2.03 and revenue of $6.86B. The stock rose 5.49% to $188.19. Analysts had lowered price targets before the report, contributing to the rally. Key questions remain about organic growth durability and valuation. Next catalysts include Q4 earnings, 2027 guidance, and analyst revisions.

$MRSHHighAI 8/10

Marsh McLennan (MRSH) Q3 2026 Earnings Call Transcript

Marsh McLennan (MRSH) reported Q3 2026 earnings with revenue up 8%, adjusted operating income up 6%, and adjusted EPS up 10%. The company highlighted growth in consulting and risk services, increased Thrive savings target to $600M, and progress in AI integration. They also repurchased $500M in stock. Market conditions showed mixed rate changes across regions and lines of business.